Azacytidine targeting SARS-CoV-2 viral RNA as a potential treatment for COVID-19  

氮杂胞苷靶向SARS-CoV-2病毒RNA作为治疗COVID-19的潜在药物

作　　者：Xian Lin Xianliang Ke Xiaoqin Jian Lin Xia Yang Yang Tianying Zhang Hualong Xiong Binghai Zhao Wen Liu Quanjiao Chen Chong Tang 林显;柯贤良;蹇晓沁;夏琳;杨洋;张田英;熊华龙;赵冰海;刘文;陈全姣;唐冲(CAS Key Laboratory of Special Pathogens and Biosafety,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430071,China;Fujian Provincial Key Laboratory of Innovative Drug Target Research,School of Pharmaceutical Sciences,Xiamen University,Xiamen 361102,China;Shenzhen Key Laboratory of Pathogen and Immunity,National Clinical Research Center for Infectious Disease,State Key Discipline of Infectious Disease,Shenzhen Third People’s Hospital,Shenzhen 518020,China;State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,National Institute of Diagnostics and Vaccine Development in Infectious Diseases,School of Public Health,Xiamen University,Xiamen 361102,China;Department of Pathophysiology,School of Medicine,Beihua University,Jilin 132011,China)

机构地区：[1]CAS Key Laboratory of Special Pathogens and Biosafety,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430071,China [2]Fujian Provincial Key Laboratory of Innovative Drug Target Research,School of Pharmaceutical Sciences,Xiamen University,Xiamen 361102,China [3]Shenzhen Key Laboratory of Pathogen and Immunity,National Clinical Research Center for Infectious Disease,State Key Discipline of Infectious Disease,Shenzhen Third People’s Hospital,Shenzhen 518020,China [4]State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,National Institute of Diagnostics and Vaccine Development in Infectious Diseases,School of Public Health,Xiamen University,Xiamen 361102,China [5]Department of Pathophysiology,School of Medicine,Beihua University,Jilin 132011,China

出　　处：《Science Bulletin》2022年第10期1022-1025,M0003,共5页科学通报（英文版）

基　　金：supported by the Key Project of Novel Coronavirus Normalized Prevention and Control in Hubei Province(2021ACB003);the National Science and Technology Major Projects(2020ZX10001016);the Natural Science Foundation of Fujian Province(2020J02004)。

摘　　要：The COVID-19 pandemic is a global health crisis.Moreover,emerging mutated virus strains present an even greater challenge for existing vaccines and medications.One possible solution is to design drugs based on the properties of the virus epigenome.报道了一种美国食品药品监督管理局批准用于治疗骨髓发育异常综合征的药物:氮杂胞苷(Azacytidine),其具有显著的体外抑制新型冠状病毒增殖的能力.小鼠体内实验表明,氮杂胞苷能够显著改善新型冠状病毒感染引起的肺部损伤,提升小鼠在病毒感染后的存活率.进一步的研究发现,氮杂胞苷能够整合到病毒基因组RNA中.氮杂胞苷是胞苷类似物,能够通过与RNA甲基转移酶结合而抑制RNA中m^(5)C的甲基化,因此,氮杂胞苷可能抑制新型冠状病毒基因组RNA的m^(5)C甲基化修饰.本研究证明了新型冠状病毒基因组RNA能够发生m^(5)C甲基化修饰,并且氮杂胞苷可能通过影响新冠病毒基因组m^(5)C修饰的方式抑制病毒的增殖,提示氮杂胞苷具有潜在治疗新型冠状病毒肺炎(COVID-19)的作用.

关 键 词：美国食品药品监督管理局 氮杂胞苷 新型冠状病毒 病毒基因组 病毒RNA 冠状病毒感染 体内实验 甲基转移酶 

分 类 号：TQ460.1[化学工程—制药化工]